About US
Contact us
-
Daiichi Sankyo receives Japanese marketing approval for two drugsDaiichi Sankyo has obtained marketing approval in Japan for its minnebro and tarlige tablets to treat hypertension and peripheral neuropathic pain (PNP) respectively. Minnebro was identified during a2019/1/11
-
FDA grants breakthrough therapy status to crizanlizumabNovartis has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for the use of crizanlizumab (SEG101) to prevent vaso-occlusive crises (VOCs) in sickle cell diseas2019/1/10
-
UC Berkeley develops drug sponge to soak up chemotherapy side effectsChemical engineers at the University of California, Berkeley (UC Berkeley) have developed a drug sponge that could absorb the residual chemotherapy drug and minimise cancer treatment side effects. To2019/1/10
-
Lilly to acquire Loxo Oncology in deal valued at $8bnEli Lilly has signed a definitive agreement to acquire Loxo Oncology, a biopharmaceutical firm focussed on genomically defined cancers, for a cash consideration of around $8bn, or $235 per share. The2019/1/9
-
Takeda completes $62bn Shire acquisitionJapan-based Takeda Pharmaceutical has officially completed the acquisition of UK headquartered Shire for a total consideration of $62bn. This makes Takeda one of the top ten pharmaceutical companies i2019/1/9
-
Eli Lilly grabs spotlight at J.P. Morgan with $8B Loxo Oncology buyoutOn the first day of biopharma’s largest confab, the J.P. Morgan Healthcare Conference, Eli Lilly confirmed that big-ticket M&A is back in fashion in the industry. Lilly said it will acquire targe2019/1/8
-
Could Gilead, Amgen and AbbVie follow Bristol-Myers into megadeal territory?Bristol-Myers Squibb’s Thursdayannouncementthat it would nab Celgene for $74 billion brought “megamergers back to pharma,” as Credit Suisse analyst Vamil Divan put it in a note to clients. And the ret2019/1/8
-
AstraZeneca’s Fasenra puts more pressure on GSK’s Nucala with expanded NICE backingBack in mid-2018, AstraZeneca’s Fasenra hit a speed bump as England’s drug cost watchdog recommended it only when GlaxoSmithKline’s rival asthma drug Nucala wasn’t appropriate. But now, the AZ drug is2019/1/7
-
Fujifilm plans $20M U.S. facility for burgeoning interest in stem cell treatmentsA host of companies are developing regenerative treatments that lean on stem cells. Seeing an opportunity, Japan’s Fujifilm will build a U.S. stem cell manufacturing facility not only for its own effo2019/1/7
-
Ex-Teva chairman Phillip Frost pays $5.5M to settle 'pump-and-dump' chargesHealthcare billionaire and former Teva chairman Philip Frost has agreed to settle stock “pump-and-dump” charges with the Securities and Exchange Commission by paying $5.5 million. Frost, without admi2019/1/4